AR and breast cancer: In conjunction with TRIM33 being identified by all three interactomes, further support for investigating the role for TRIM33 in ER+ breast cancer comes from findings in prostate cancer cells where TRIM33 modulates the activity of another nuclear hormone receptor, the androgen receptor [33].